A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
Experimental: 68Gallium PSMA-PET/CT

Patients will initially undergo a standard of care FDG PET with diagnostic CT scan followed by an investigational 68Ga PSMA PET/CT scan.

Drug: [68Ga]PSMA

68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

Diagnostic Test: PET/CT imaging

68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 4, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments